ArticleJournal for immunotherapy of cancer2025

Correction: Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.

No numbers read from the abstract.

Not cited yet